80 results
8-K
EX-99.1
LCTX
Lineage Cell Therapeutics, Inc.
8 Aug 24
Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
4:10pm
) clinical study for the treatment of subacute and chronic spinal cord patient start-up activities continue.
oHosted the 2nd Annual Spinal Cord Injury
424B5
LCTX
Lineage Cell Therapeutics, Inc.
14 May 24
Prospectus supplement for primary offering
4:36pm
to administer OPC1 to the spinal parenchyma in subacute and chronic SCI patients. We have received written correspondence from the FDA, advising us … the safety and utility of a novel spinal cord delivery device in both subacute and chronic spinal cord injuries and continues to be evaluated in long-term
8-K
EX-99.1
LCTX
Lineage Cell Therapeutics, Inc.
9 May 24
Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
4:10pm
of Oligodendrocyte Progenitor Cells for Spinal Cord Injury: Evaluation of a Novel Device) clinical study for the treatment of subacute and chronic spinal cord patient
424B5
h2lou8hx
22 Mar 24
Prospectus supplement for primary offering
4:32pm
8-K
EX-99.1
tff3jll
7 Mar 24
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4:10pm
424B5
nf8n8s35pbqi8
6 Feb 24
Prospectus supplement for primary offering
9:25am
8-K
EX-99.1
k626i3cs0a9e
9 Nov 23
Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
4:10pm
8-K
EX-99.1
wnz bhcpv39i1qogwi
12 Aug 21
LINEAGE REPORTs SECOND QUARTER 2021 FINANCIAL RESULTS AND HIGHLIGHTS ADDITIONAL PROGRESS FROM CLINICAL CELL THERAPY PROGRAMS
4:10pm
8-K
5szpp643vjs1gkc77
1 Mar 19
Other Events
12:00am
425
3q96waemzxhxwl8
1 Mar 19
Business combination disclosure
12:00am
424B3
1v99jic7ya
4 Feb 19
Prospectus supplement
5:52pm